Objective: Very-low-calorie diets (VLCDs) are used to promote short-term weight loss in obese patients. However, long-term maintenance of weight loss is generally poor. We assessed the efficacy and safety of sibutramine in maintaining weight loss achieved in obese patients by means of a 3-month VLCD. Design: A multicenter double-blind, parallel-group trial conducted over 18 months, following a 3-month open label VLCD runin. Setting: Eight hospital centers in The Netherlands, with subsequent follow-up in general practice. Subjects: A total of 221 obese subjects, of whom 189 were randomized (mean screening BMI 36.6 kg/m 2 ; mean age 42.6 y). Measurements: Patients were given a 3-month VLCD and were required to lose 10% or more of their initial weight. A total of 189 patients completed this phase (mean percentage weight loss 14.573.2%) and were randomized to sibutramine 10 mg/day (n ¼ 94) or matching placebo (n ¼ 95). All patients received a recommended diet and exercise program. The primary analysis was outcome in terms of achieving 80% weight maintenance of the VLCD period at month 18. Secondary analysis was percentage of initial weight loss maintained at months 6, 12, 18 and end point. Results: At month 18, the odds ratio for achieving successful weight maintenance was 1.76 (95% CI 1.06, 2.93) in favor of sibutramine (P ¼ 0.03). In intention-to-treat analysis, more than 80% of the weight loss achieved during the VLCD phase was maintained by 70, 51 and 30% of sibutramine-treated patients at months 6, 12 and 18, respectively, compared to 48, 31 and 20% of placebo-treated patients. The differences between the treatment groups were significant (Pr0.03) at all time points. Conclusion: Weight loss achieved with a VLCD is more effectively maintained with sibutramine in combination with a recommended diet and exercise program than with placebo over a follow-up period of 18 months. Sibutramine is well tolerated, with a safety profile consistent with that seen in other previous trials.
Introduction
Obesity is a common problem that predisposes patients to hypertension and cardiovascular disease, diabetes mellitus, hormone-related cancers, gallbladder disease, musculoskeletal disorders, sleep apnea and generalized bodily pain. It has a detrimental effect on social well-being, decreases longevity and imposes a financial and time burden on health care systems (National Heart, Lung and Blood Institute, 1998; Royal College of Physicians, 1998) . The continuing worldwide epidemic of obesity, and its consequences in terms of obesity-related diseases, illustrates the need for the development of effective treatment strategies (World Health Organization, 2000) .
The recommended treatment for the obese patient is diet modification and increased physical activity (National Heart, Lung and Blood Institute, 1998) . However, lifestyle interventions alone generally have a poor success rate, even when long-term intensive follow-up is provided (Garrow, 1992; Anderson et al, 1999) .
Very-low-calorie diets (VLCDs) are well established as a means of promoting significant short-term weight loss, with concomitant improvement in obesity-related conditions, in moderately and severely obese patients at high risk from their obesity (body mass index (BMI)430 kg/m 2 ); however, long-term maintenance of weight lost with VLCDs is unsatisfactory (National Task Force on the Prevention and Treatment of Obesity and National Institutes of Health, 1993) . Although weight maintenance can be improved by active follow-up with behavioral therapy, nutritional education and exercise (Saris, 2001) , the use of antiobesity medications offers a further opportunity for improving the maintenance of weight loss. Authoritative management guidelines acknowledge that pharmacotherapy can be an important component of weight loss programs (National Task Force on the Prevention and Treatment of Obesity, 1996; Royal College of Physicians of London, 2003) ; studies conducted in obese patients have shown that the noradrenaline and serotonin reuptake inhibitor, sibutramine, can result in clinically significant weight loss and weight maintenance for up to 24 months (James et al, 2000) .
The present study sought to assess the efficacy and safety of sibutramine in combination with a recommended diet and exercise program in a general practitioner (GP) setting on the maintenance of weight loss in obese patients who had successfully lost weight on a 3-month VLCD.
Methods
This was a multicenter parallel-group trial designed to evaluate over an 18-month double-blind period, the efficacy and safety of sibutramine compared to placebo, each combined with diet and exercise, in maintaining weight loss induced by a VLCD.
The initial 5-month phase of the trial was conducted by specialists in eight hospital centers in The Netherlands (Almelo, Amsterdam, Beverwijk, Brunssum, Gouda, Stadskanaal, Tilburg and Utrecht). During this phase, the VLCD was administered and drug therapy was initiated. Follow-up over the remaining 13 months was undertaken in 61 general practice and 27 dietetic centers in The Netherlands, with occasional, planned visits to the specialist.
The study protocol was reviewed and approved by an independent National Ethics Committee and the study was conducted in accordance with the principles of the Declaration of Helsinki. All participants gave written informed consent to participate in the study at the screening visit.
Patients
Patients were recruited from general practice and medically screened for inclusion in the trial. Men or women aged 18-65 y were eligible if they had a BMI within the range of 30-45 kg/m 2 and had not used any prescription weight loss agent within the last 6 months (whether on prescription or in a clinical trial), or received surgical treatment for weight reduction. Subjects were excluded if they had weight change of more than 3 kg in the previous 3 months, obesity of endocrine origin, and type I diabetes mellitus or type II diabetes mellitus requiring oral hypoglycemic medication unless they were stabilized on their oral hypoglycemic medication for at least 6 months. Hypertensive patients stabilized on therapy were eligible to participate in the trial but those with a diastolic blood pressure greater than 95 mmHg or a systolic blood pressure greater than 160 mmHg were not. Patients with a seated pulse rate exceeding 100 beats/min were also excluded.
Patients were also excluded if they had any history of significant neurological or psychiatric illness, a history of alcohol or drug abuse, significant hepatic or renal dysfunction, pulmonary disease, cerebrovascular disease or cardiac dysfunction. Pregnant and lactating women were excluded, as were those seeking to become pregnant. Patients were excluded if in the previous 3 months they had taken anorectic agents, oral steroids, oral beta-agonists, other medications known to affect appetite, thyroid preparations (unless stabilized for 6 months), laxatives (unless prescribed at recommended doses where medically indicated) or other medications that might interfere with the processes of absorption, metabolism or excretion. Use of hormone replacement therapy or lipid-lowering drugs was permitted where these were stabilized over the previous 3 months. Starting any of the above-mentioned medication during the trial was also prohibited.
Study design and treatment
All patients were screened for eligibility at the initial screening visit by their GP. Those patients deemed eligible for the trial subsequently met with the internist and dietitian and entered the VLCD run-in period (month À3), during which no study medication was taken and all patients' meals were replaced by a VLCD (Modifast, Novartis Medical Nutrition) providing a total daily caloric content of 480 kcal to be divided into breakfast, lunch and evening meal; no other caloric intake was permitted.
A 2 weeks before the end of the 3-month VLCD phase, there was a staged re-introduction of regular meals with the evening VLCD meal replaced by normal food. After a further 2 weeks (ie at the baseline (month 0) visit), lunch was replaced by normal food, and after a further 2 weeks, all meals consisted of normal food. The caloric content of the daily intake during the remainder of the trial was calculated to deliver a 600 kcal deficit according to assessment of each individual patient's resting metabolic rate multiplied by 1.3 (World Health Organization, 1985) .
Those patients who had lost the required minimum of 10% of their screening bodyweight at the end of the run-in period were eligible to enter the 18-month double-blind treatment phase, during which they were allocated a unique medication number and randomized by a computer-generated list to receive either capsules containing sibutramine 10 mg or matching placebo, to be taken once daily before breakfast. Dose increase to sibutramine 15 mg or placebo 15 mg was permitted 6 months after randomization if patients experienced weight gain of more than 3 kg from their baseline (month 0) weight. At month 19, a post-study follow-up visit was included to record any changes in weight after discontinuing the study medication and to monitor safety.
Study assessments
At the screening visit, a medical history was taken and patients underwent a full physical examination with an electrocardiogram, blood pressure and pulse recorded, along with weight, waist and hip circumference measurements. A fasting blood sample was taken for laboratory tests (full blood count, serum electrolytes, uric acid, creatinine, hepatic enzymes, lipoprotein levels and urinalysis).
During the VLCD run-in, patients visited the dietitian and hospital internist every 2 weeks. During the 18-month double-blind phase, patients visited the internist every 2 weeks during the first 2 months, and for the remaining study period visited their GP and the dietitian at monthly intervals until month 12 and then alternating every month. On months 3, 6, 12 and 18, the patient also visited the internist.
At all visits, the patient's weight was recorded to the nearest 0.1 kg with the patient wearing indoor clothing and no shoes. Waist and hip circumferences were also measured during these visits.
Blood pressure, pulse, adverse events and concomitant medications were recorded at baseline and at months 1-7, months 9, 11, 13, 15, 17, 18 and 19 (ie the follow-up visit). Laboratory measurements (hematology, biochemistry and urine analysis) were performed on blood samples taken at baseline and months 6, 12 and 18 (or on withdrawal).
To assess compliance, unused trial medication was returned by the patient and counted by the investigator each month and at withdrawal.
Patients were able to withdraw from the trial at any time giving the primary reason for withdrawal. In such a case, assessment as for month 18 was completed and patients were asked to return for a follow-up visit 1 month after withdrawal (if possible), which included all of the required evaluations and observations.
Statistical analyses
The sample size for the study was derived assuming an odds ratio of 1.52 in favor of sibutramine, that is, a 50% greater chance of weight loss maintenance on sibutramine based on data derived from previous studies in a similar population. Based on a 5% significance level, 90% power and a classification of weight loss maintenance as used in previous studies, 130 patients were required to enter the double-blind phase of the study. Assuming that 45% of patients would fail to achieve the 10% weight loss criterion during the VLCD phase to qualify for randomization, 240 patients needed to be recruited.
The primary end point was the outcome in terms of final status of the patient at month 18. All data from these patients were included in an outcome analysis with treatment-related withdrawals (ie adverse events, lack of efficacy) assigned a value equivalent to the worst percentage regain. Values for other withdrawals were assigned to the second worst percentage weight regain apart from withdrawals due to treatment success, which were assigned to the best outcome category. For all other patients, the percentage weight loss maintained at month 18 was taken as the outcome and categorized as r40% maintained; 440 and r60% maintained; 460 and r80% maintained; 480 and r100% maintained; 4100% maintained. The difference in outcome score between treatment groups was analyzed by proportional odds logistic regression, with bodyweight at screening and weight lost during the VLCD period as covariates and treatment group, and center as factors.
The percentage of weight loss, between screening and baseline (month 0), that was maintained at months 6, 12, 18 and end point was analyzed by analysis of covariance with the same factors and covariates as described above.
All statistical tests were two-tailed with significance determined by reference to the 5% level. The null hypothesis was that sibutramine and placebo were equal. All treatment comparisons were reported with 95% confidence intervals.
All results were analyzed on an intention-to-treat basis (defined as those patients who took at least one dose of trial medication); for subjects who withdrew, their last weight constituted the end point of the trial.
Adverse events were classified according to COSTART; events classified by the investigator as having no relationship to therapy were disregarded.
Results

Patients
A total of 221 patients entered the VLCD period, of which 201 patients completed. A total of 189 (94%) lost Z10% of their screening bodyweight in the VLCD period, and were eligible for randomization. The mean weight loss from screening to baseline for these patients was 15.274.0 kg (14.573.2%). Of the patients randomized, 94 were assigned to sibutramine and 95 to placebo. The treatment groups were comparable at screening and at baseline ( Table 1) .
The number of patients who completed the 18-month double-blind phase was similar in the sibutramine and placebo groups (61 (65%) and 58 (61%), respectively). A total of 70 patients withdrew from the study, 33 (35%) in the sibutramine group and 37 (39%) in the placebo group (P ¼ 0.49). There was no significant difference between treatment groups in the overall withdrawal rate, or in the withdrawal rate due to treatment-related reasons. Most withdrawals were due to protocol violations (13 in the sibutramine group and 12 in the placebo group), while adverse events accounted for six withdrawals from the sibutramine group and eight in the placebo group.
A total of 10 patients (two in the sibutramine group and eight in the placebo group) were considered noncompliant with trial medication at one or more visits based on returned medication counts calculated at less than 70%. Most patients in both groups rated their adherence to dietary advice as moderate or better than moderate; there were no significant differences between treatment groups at month 18 and end point and similar results were seen with investigator-assessed adherence to dietary advice.
The protocol allowed for the dose of trial medication to be increased to 15 mg at the month 6 visit if the patient had gained more than 3 kg compared to the baseline assessment. A statistically significantly higher proportion of patients in the placebo group (31/95; 33%) increased to the 15 mg dose compared to the sibutramine group (13/94; 14%; P ¼ 0.002 w 2 test).
Weight loss and weight loss maintenance
The pattern of weight loss from screening to month 18 for the observed intent-to-treat population is illustrated in Figure 1 . At end point, the overall mean (7s.d.) change from the start of the VLCD phase to month 18 was À10.777.5 kg (À10.377.0%; n ¼ 94) in the sibutramine group compared to À8.578.1 kg (À7.977.3%; n ¼ 95) for patients who received placebo. For completers, the mean changes to month 18 were À12.377.6 kg (À11.977.1%; n ¼ 62) vs À7.978.3 kg (À7.377.4%; n ¼ 58), respectively.
The difference between treatment groups in the change from baseline (month 0) body weight significantly favored the sibutramine group at month 18 and end point (Po0.008). For placebo-treated patients, there was a mean increase in body weight from baseline to end point of 6.7 kg compared with 4.1 kg for patients who received sibutramine (P ¼ 0.008). The mean percentage weight change for patients who received placebo was 7.6% compared with 4.5% for patients who received sibutramine (P ¼ 0.004).
Patients who received sibutramine during the doubleblind phase of this trial showed a better outcome for weight loss maintenance (defined as maintaining Z80% of the weight lost during the VLCD period) than patients who received placebo. The differences between the treatment groups were significant (Pr0.03) at all time points analyzed (months 6, 12, 18 and end point).
At least 80% of the weight loss during the VLCD period was maintained by 70, 51 and 30% of sibutramine-treated patients at months 6, 12 and 18, respectively, compared to 48, 31 and 20% of placebo-treated patients, respectively, based on the outcome score analysis (Pr0.03). At month 18, the odds ratio for achieving successful weight maintenance was 1.76 (95% CI 1.06, 2.93) in favor of sibutramine (P ¼ 0.03).
Among study completers, logistic regression modeling showed that more patients who received sibutramine achieved successful weight maintenance compared with patients who received placebo. At month 6, 80% of sibutramine patients and 56% of placebo patients had achieved successful weight maintenance (Po0.001). Comparable figures at months 12 and 18 were 63 vs 38% (P ¼ 0.0012) and 47 vs 33% (not significant; P ¼ 0.07), respectively. Successful weight maintenance at end point was achieved by 46% of the patients who received sibutramine and 36% of the patients treated with placebo (P ¼ 0.11).
During the 18-month double-blind phase of the trial, more patients who received placebo experienced a loss of weight maintenance (defined as returning to below 80% of weight lost during the VLCD phase) compared to sibutraminetreated patients (64 vs 54%). The time to first occurrence of this event was significantly longer for patients who received sibutramine throughout the trial: the Kaplan-Meier median estimate was 511 days for sibutramine-treated patients compared to 486 days for those randomized to placebo (P ¼ 0.02).
Other outcomes
Changes in body size variables were consistent with the weight change profile (Table 2) . Improvements achieved during the VLCD phase were still apparent at end point in both treatment groups, but were maintained more consistently in the sibutramine group than in the placebo group.
Among the patients who successfully maintained at least 80% of the total weight lost during VLCD phase, those patients who received sibutramine showed additional mean decreases in waist circumference (À1.7 cm), hip circumference (À0.5 cm) and waist/hip ratio (À1.1) from baseline to end point.
Improvements in metabolic variables achieved during the VLCD phase were also generally maintained to both month 18 and end point (Table 3) . Patients who received placebo during the double-blind phase experienced a greater percentage increase in triglycerides, LDL-cholesterol and HDL/LDLcholesterol ratio than patients who received sibutramine. These differences were not statistically significant.
Safety
Overall, 157 (83%) patients reported 662 adverse events during the double-blind phase. The number of adverse events reported by patients receiving sibutramine and placebo was not statistically different (P ¼ 0.46). Serious adverse events during the double-blind phase were reported by 9 (10%) patients in the sibutramine group and 14 (15%) patients in the placebo group; most were considered unlikely to be related to trial medication. One patient, in the placebo group, experienced severe dyspnea and was diagnosed with a carcinoma of the lung. Treatment was stopped and she was hospitalized. At 1 month after trial medication was stopped, the patient died.
Large reductions in vital signs were recorded in both patient groups during the VLCD phase of the study (Table 4) . Subsequently, during the active treatment phase, blood pressure values remained considerably below screening levels at both month 18 and end point in the sibutramine and placebo groups. Pulse rate, however, had returned to prescreening levels in both groups. The difference between the treatment groups in the change from baseline to both month 18 and end point was not significant for blood pressure or heart rate.
For the subset of patients treated with sibutramine who achieved successful weight maintenance, the changes in blood pressure from baseline to end point were smaller than the corresponding values for all patients who received sibutramine during the double-blind phase.
Discussion
This trial has demonstrated that weight loss achieved with a VLCD is more effectively maintained with sibutramine in combination with a recommended diet and exercise program than with placebo over a follow-up period of 18 months.
Obesity is a chronic, life-long condition with a natural history of progressive weight gain. The recognition that modest sustained weight loss (Z5% of initial weight) can impart significant health benefits and that a return to 'normal' weight is rarely achieved have all contributed to a redefinition of success criteria in weight management (World Health Organization, 2000) . Success is now defined in terms of decreasing the severity of obesity (achieving a healthy weight) rather than 'curing' it by returning to a 'normal' weight. Furthermore, the treatment of obesity should be aimed at both weight reduction and maintenance of the weight lost (Royal College of Physicians, 1998) . It is well accepted that modest weight loss, in the range of 5-10% of initial body weight, is sufficient to improve many obesity-related conditions. Two large, prospective randomized studies have independently demonstrated that overweight patients who lost approximately 5% of their body weight reduced their risk of developing type II diabetes mellitus by 58% (Tuomilehto et al, 2001; Knowler et al, 2002) . Weight reduction of any amount in women with obesity-related conditions who had never smoked, 40-64 y of age, was associated with a reduction in all-cause mortality of 20% and diabetes-associated mortality by 30-40% (Williamson et al, 1995) . Modest weight reduction has also been associated with clinically significant improvements in hypertension (Tuck et al, 1981) , lipid abnormalities (Dattilo & Kris-Etherton, 1992 ) and glycemic control (UK prospective study of therapies of maturity-onset diabetes, 1983).
However, most treatment approaches that rely on dietary and activity interventions along with behavior modification generally have a poor success rate (Garrow, 1992) . Most patients regain weight once obesity treatment is discontinued.
VLCDs are generally reserved for very obese individuals who need to lose weight rapidly for health reasons; they should only be used under strict medical supervision, usually for a maximum of 3 months. Our study confirmed the value of the VLCD as a tool for successful weight loss; 189 of 221 patients who entered the open-label VLCD phase of the trial were able to lose 10% of their screening bodyweight, with an overall mean weight loss from screening to baseline of 15.2 kg. Although we also observed weight regain following the VLCD phase, the regain was less in those patients treated subsequently with sibutramine than those who received the same diet and exercise regimen without sibutramine.
Sibutramine has previously been shown in randomized controlled studies to be an effective agent for inducing weight loss and weight maintenance in conjunction with lifestyle and dietary advice, resulting in weight loss of 5-10% in most patients (Bray et al, 1999; James et al, 2000; Smith & Goulder, 2001; Wirth & Krause, 2001) . Weight maintenance after a VLCD was examined in one study by Apfelbaum et al (1999) , in which patients who had lost 6 kg or more during a 4-week treatment with a VLCD were subsequently treated with sibutramine 10 mg once daily for 12 months. In that study, patients continued to lose weight. In comparison, the mean weight loss after the VLCD period in our study (15.274.0 kg) was more than twice that achieved by Apfelbaum; however, patients in our study did not continue to lose weight. This is probably explained by the longer VLCD phase and overall duration of our study.
The Sibutramine Trial of Obesity Reduction and Maintenance (STORM) also examined maintenance of weight loss (James et al, 2000) . In this study, maintenance of weight loss of Z5% for 18 months was achieved by 69% of the patients by combining diet and exercise modifications with sibutramine. Successful weight maintenance (Z80% of the weight lost prior to randomization) was achieved by 43% of patients treated with sibutramine compared to 16% of patients on placebo in a strictly controlled academic setting.
In a GP setting, the percentage of sibutramine-treated patients (47%) with successful weight maintenance during the double-blind period (maintenance of at least 80% of the weight lost between screening and baseline) was similar to that seen in STORM. In STORM, almost all patients received sibutramine 15 or 20 mg, whereas in our study, only 14% of patients received the higher permitted dose of 15 mg. However, we also observed a higher success rate in our placebo group patients (33%), possibly reflecting the greater initial weight loss following the VLCD.
The changes in lipid profile and vital signs were consistent with the pattern of weight loss. Initial improvements that occurred during the VLCD phase were attenuated by trial end, but remained generally positive. Significant differences were not apparent between sibutramine and placebo therapy at end point. The initial decrease in HDLcholesterol that occurred with early weight loss is consistent with previous observations, and was ameliorated by the end of the study.
While the efficacy results from this study are encouraging, it should be noted that the study encompassed a number of factors that may have affected the trial results. Considerably less support was available to patients during the weight maintenance phase in relation to the VLCD phase. It is likely that even better weight loss maintenance could have been achieved with continued intensive support. Nevertheless, the result reflects the more realistic outcome likely in general practice. Likewise, the effectiveness of treatment with sibutramine may also have been under-represented, particularly since there was only a limited possibility for increasing the dose of sibutramine throughout the weight maintenance phase, which clearly would not apply in clinical practice.
This study provides reassuring evidence of the safety of sibutramine in this setting where a major part of the guidance was offered by the GP and a dietitian. Despite a high overall incidence of reported adverse events (83%), the study had a relatively low dropout rate, with only around seven patients from each arm of the trial withdrawing due to adverse events. The incidence and type of adverse events were similar for both treatment groups, and the adverse event profile was similar to that previously observed for sibutramine (Lean, 1997) . Although the initial improvements in blood pressure and heart rate that resulted from the VLCD-induced weight loss were attenuated during the double-blind treatment phase, the end-point results remained favorable, and were not significantly different between treatment groups.
In conclusion, following a 3-month VLCD, obese patients treated with sibutramine for 18 months were better able to maintain their weight loss than placebo-group patients.
